6 companies in Gene & cell engineering.
Intellia Therapeutics
Gene & cell engineering · Gene editing inside the body
Latest (Sep 8, 2026): Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Open profile →Beam Therapeutics
Gene & cell engineering · Base editing
Latest (Aug 4, 2026): Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Open profile →CRISPR Therapeutics
Gene & cell engineering · CRISPR gene-editing medicines
Latest (Oct 19, 2026): CRISPR Therapeutics reports changes involving its directors or officers (Form 8-K, Item 5.02)
Open profile →Prime Medicine
Gene & cell engineering · Prime editing
Latest (Aug 6, 2026): Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Open profile →Sana Biotechnology
Gene & cell engineering · Regeneration · Engineered cells as medicines
Latest (Aug 10, 2026): Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Open profile →Rejuvenate Bio
Longevity · Gene & cell engineering · Gene therapy for ageing-related disease
Latest (Jun 18, 2026): Rejuvenate Bio reports $19.5 million of equity sold in a private offering
Open profile →Coverage is not an offer to invest. Private ownership does not imply available shares. Sector labels are Sapien Frontier’s own coverage classification, not company claims.
Missing a company? Request future coverage. We add a company when its filings, offering notices or awards can be followed reliably. See what we cover and how often.